Evidence map›Paper›PMID 37247081›Full record

ArticleJournal of cancer research and clinical oncology2023

Based on disulfidptosis, revealing the prognostic and immunological characteristics of renal cell carcinoma with tumor thrombus of vena cava and identifying potential therapeutic target AJAP1.

Lin Yang, Jiahao Liu, Sheng Li, Xiaoqiang Liu, Fuchun Zheng, Songhui Xu, Bin Fu, Jing Xiong

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
13.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 45 citations in OpenAlex.

  1. The emerging roles of disulfidptosis in cancer.Apoptosis : an international journal on programmed cell death · 2026
    Review
  2. Disulfidptosis: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Lin YangDepartment of Urology, First Affiliated Hospital of Nanchang University, Nanchang, 330000, China.
Jiahao LiuDepartment of Urology, First Affiliated Hospital of Nanchang University, Nanchang, 330000, China.
Sheng LiDepartment of Urology, First Affiliated Hospital of Nanchang University, Nanchang, 330000, China.
Xiaoqiang LiuDepartment of Urology, First Affiliated Hospital of Nanchang University, Nanchang, 330000, China.
Fuchun ZhengDepartment of Urology, First Affiliated Hospital of Nanchang University, Nanchang, 330000, China.
Songhui XuDepartment of Urology, First Affiliated Hospital of Nanchang University, Nanchang, 330000, China.
Bin FuDepartment of Urology, First Affiliated Hospital of Nanchang University, Nanchang, 330000, China. urofbin@163.com.
Jing XiongDepartment of Urology, First Affiliated Hospital of Nanchang University, Nanchang, 330000, China. alex7023@126.com.
First Affiliated Hospital of Nanchang University · CNNanchang University · CN

Funding

Jiangxi Provincial "Double Thousand Plan" Fund Project jxsq2019201027Jiangxi Provincial Health Technology Projec 202210339Key Project of Natural Science Foundation of Jiangxi Province 20212ACB206013Youth Project of Natural Science Foundation of Jiangxi Province 20212BAB216037
6 · The paper itself

Abstract

backgroundPatients with clear cell renal cell carcinoma (ccRCC) with venous tumor thrombus have a poor prognosis, high surgical risk, and lack of targeted therapeutic agents.

methodsGenes with consistent differential expression trends in tumor tissues and VTT groups were first screened, and then differential genes associated with disulfidptosis were found by correlation analysis. Subsequently, identifying ccRCC subtypes and constructing risk models to compare the differences in prognosis and the tumor microenvironment in different subgroups. Finally, constructing a nomogram to predict the prognosis of ccRCC and validate key gene expression levels in cells and tissues.

resultsWe screened 35 differential genes related to disulfidptosis and identified 4 ccRCC subtypes. Risk models were constructed based on the 13 genes, and the high-risk group had a higher abundance of immune cell infiltration, tumor mutational load, and microsatellite instability scores, predicting high sensitivity to immunotherapy. The 1-year AUC = 0.869 for predicting OS by nomogram has a high application value. The expression level of the key gene AJAP1 was low in both tumor cell lines and cancer tissues.

conclusionsOur study not only constructed an accurate prognostic nomogram for ccRCC patients but also identified an AJAP1 biomarker as a potential biomarker for the disease.

Indexed as

CarcinomaCarcinoma, Renal CellKidney NeoplasmsApoptosisCell Adhesion MoleculesDisulfidesHumansNomogramsPrognosisTumor MicroenvironmentAJAP1 protein, humanCell Adhesion MoleculesDisulfidesClear cell renal cell carcinomaDisulfidptosisImmunotherapyTumor microenvironmentVenous tumor thrombus

Identifiers

PMID37247081
PMCPMC11796798
OpenAlexW4378640354

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.